Acorda Therapeutics, Inc.【ACOR】 業績推移・財務諸表

(単位:千ドル) 2Q10 3Q10 1Q11 2Q11 3Q11 4Q11 1Q12 2Q12 3Q12 4Q12 1Q13 2Q13 3Q13 4Q13 1Q14 2Q14 3Q14 4Q14 1Q15 2Q15 3Q15 4Q15 1Q16 2Q16 3Q16 4Q16 1Q17 2Q17 3Q17 4Q17 1Q18 2Q18 3Q18 4Q18 1Q19 2Q19 3Q19 4Q19 1Q20 3Q20 1Q21 2Q21 3Q21 1Q22 2Q22 3Q22 1Q23 2Q23 3Q23 1Q24
売上高 42,835 63,622 61,286 65,276 93,031 72,644 71,248 75,656 77,437 81,473 71,865 87,053 84,919 92,593 80,518 97,129 105,961 117,872 99,851 113,707 148,199 130,903 115,904 127,458 135,613 140,627 119,386 139,438 141,065 188,398 106,165 153,302 142,814 69,152 44,137 50,053 47,722 50,496 28,099 53,090 28,862 31,785 31,456 22,534 31,051 33,511 22,258 29,675 27,715 20,289
売上成長率(%) - - - - -
売上原価 7,831 11,666 12,050 12,048 26,651 - 12,464 13,576 14,761 - 13,484 16,935 17,213 - 15,529 18,899 20,575 - 18,446 22,708 24,741 - 23,186 26,435 27,644 - 25,183 29,665 29,992 - 21,350 31,094 25,391 - 8,799 9,397 7,986 - 3,843 12,170 11,961 11,324 13,303 5,967 8,800 11,005 3,234 3,065 3,387 3,707
研究開発費 6,595 7,970 10,708 12,008 9,088 - 11,025 12,634 12,031 - 12,520 13,216 13,839 - 14,522 16,448 16,578 - 30,636 31,229 43,356 - 44,570 50,293 54,777 - 46,493 51,184 33,286 - 30,560 25,910 22,855 - 16,028 18,959 16,073 - 7,705 5,729 4,749 2,374 1,931 1,694 1,525 1,383 1,386 1,550 1,207 954
販売管理費 34,111 30,723 38,087 40,300 34,718 - 38,745 44,230 40,121 - 48,198 48,003 42,336 - 46,892 50,644 47,820 - 48,769 52,819 51,056 - 58,980 62,604 54,805 - 52,024 49,334 40,741 - 47,601 44,263 43,571 - 52,725 50,195 48,702 - 41,108 39,935 33,968 32,368 29,623 26,938 30,067 22,997 22,514 21,825 23,152 28,371
営業費用 48,539 50,359 60,845 64,356 72,365 - 62,393 70,598 67,072 - 74,361 78,313 73,547 - 77,102 86,150 85,132 - 101,110 108,015 122,512 - 133,095 141,491 141,085 - 134,659 136,742 143,224 - 105,711 94,267 114,517 - 87,516 73,442 307,072 - 34,268 37,053 57,643 47,474 54,465 39,237 44,966 38,500 33,734 33,307 30,234 39,917
営業利益 -5,704 13,262 441 920 20,666 - 8,855 5,058 10,365 - -2,496 8,740 11,372 - 3,416 10,979 20,829 - -1,259 5,692 25,687 - -17,191 -14,033 -5,472 - -15,273 2,696 -2,159 - 454 59,035 28,297 - -43,379 -23,389 -259,350 - -6,169 16,037 -28,781 -15,689 -23,009 -16,703 -13,915 -4,989 -11,476 -3,632 -2,519 -19,628
営業利益率 (%) - - - - - - - - -
経常(税引前)利益 - - -555 -223 19,853 - 8,218 4,825 10,127 - -2,914 8,157 10,990 - 3,496 10,718 16,489 - -5,123 2,127 21,711 - -10,257 -19,929 -10,009 - -19,822 -2,725 -6,327 - -4,722 54,553 24,057 - -48,320 -27,272 -263,518 - -13,470 8,812 -36,603 -23,395 -30,176 -24,264 -20,119 -12,438 -18,862 -11,346 -9,943 -27,281
経常(税引前)利益率(%) - - -0.91 -0.34 21.34 - 11.53 6.38 13.08 - -4.05 9.37 12.94 - 4.34 11.03 15.56 - -5.13 1.87 14.65 - -8.85 -15.64 -7.38 - -16.6 -1.95 -4.49 - -4.45 35.59 16.84 - -109.48 -54.49 -552.19 - -47.94 16.6 -126.82 -73.6 -95.93 -107.68 -64.79 -37.12 -84.74 -38.23 -35.88 -134.46
法人税等合計 - - -117 62 986 - 372 280 533 - -1,775 4,247 3,513 - 2,793 6,033 4,536 - -2,038 1,130 17,770 - -9,737 -972 3,023 - -918 5,471 18,868 - 3,477 8,356 37,968 - -715 200 20 - -7,000 1,500 -3,200 -500 -3,100 300 26,600 1,400 -2,000 -2,000 -1,100 100
実効税率(%) - - - - - - - - - - -
純利益 -6,763 12,437 -672 -285 18,867 12,694 - - - - - - - - - - - - - - - - - -18,279 -12,725 -3,094 -18,904 -8,196 -25,195 -171,064 -8,199 46,197 -13,911 9,595 -47,605 -27,486 -263,535 65,660 -6,472 7,347 -33,451 -22,864 -27,071 -24,522 -46,682 -13,854 -16,824 -9,381 -8,888 -27,395
純利益率(%) - - - - - - - - - - - - - - - - -
一株あたり利益 - 0.32 -0.02 -0.01 0.48 0.32 0.2 0.12 0.24 3.36 -0.03 0.1 0.19 0.15 0.02 0.11 0.29 0.01 -0.07 0.02 0.09 0.22 -0.01 -0.4 -0.28 -0.07 -0.41 -0.18 - - - 0.99 -0.29 0.2 -1 -0.58 -5.55 1.38 -0.14 0.15 -3.53 -2.29 -2.43 -1.85 -2.78 -0.57 -0.69 -7.55 -7.16 -22.06
希薄化後一株あたり利益 - 0.31 -0.02 -0.01 0.47 0.32 0.19 0.11 0.24 3.27 -0.03 0.09 0.18 0.15 0.02 0.11 0.28 0.01 -0.07 0.02 0.09 0.21 -0.01 -0.4 -0.28 -0.07 -0.41 -0.18 - - - 0.98 -0.29 0.2 -1 -0.58 -5.55 1.38 -0.14 0.05 -3.53 -2.29 -2.43 -1.85 -2.78 -0.57 -0.69 -7.55 -7.16 -22.06
EBITDA - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
EBITDAマージン(%) - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -